Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. November 2014 17:15 ET | Quelle: Lisata Therapeutics

NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial

Statistically significant mortality benefit observed in patients with acute myocardial infarction (AMI) treated with intracoronary administration of CD34 cells (NBS10; AMR-001) as well as...
12. November 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem to Present at Multiple November Conferences

NEW YORK, Nov. 12, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that the Company will present at multiple...
10. November 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Data From Phase 2 PreSERVE AMI Clinical Trial to be Presented at American Heart Association Scientific Sessions on November 17

NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today scheduling details regarding upcoming...
05. November 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Announces Additions to Management

NEW YORK, Nov. 5, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell based therapeutics, announced today the addition...
03. November 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem to Present at Multiple Conferences This Week

NEW YORK, Nov. 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics designed to prevent, treat or cure disease, announced today...
30. Oktober 2014 16:14 ET | Quelle: Lisata Therapeutics

NeoStem Announces Third Quarter 2014 Financial Results and Outlines Near Term Milestones

NEW YORK, Oct. 30, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics designed to prevent, treat or cure disease, today announced...
27. Oktober 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Announces BioProcess International Excellence in Leadership Award Given to Dr. Robert Preti, Chief Scientific Officer and President of PCT

NEW YORK, Oct. 27, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), ("NeoStem" or the "Company") a leader in the emerging cellular therapy industry, announced today that Dr. Robert Preti, the...
13. Oktober 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Ranked as One of the Fastest Growing Companies in New York City

NEW YORK, Oct. 13, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company has been named...
06. Oktober 2014 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Announces USAN Approval of Generic Name 'Eltrapuldencel-T' for Investigational Patient-Specific Targeted Cancer Immunotherapy

NEW YORK, Oct. 6, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that the United States Adopted Name Council (USAN) has...
02. Oktober 2014 16:30 ET | Quelle: Lisata Therapeutics

NeoStem to Present at Multiple October Conferences

NEW YORK, Oct. 2, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its...

Vorherige Seite

Nächste Seite